Can a GLP-1 Pill Revive Novo Nordisk?
Ed Elson speaks with Alex Heath, host of the ACCESS Podcast, about why Nvidia is dominating the news out of the CES conference. Then Jared Holz, Healthcare Equity Strategist at Mizuho, joins the show to discuss what Novo Nordisk’s new Wegovy pill means for the healthcare industry. Check out our latest Prof G Markets…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Prof G Markets →
The State of Weight-Loss Drugs
Here's How the New Weight Loss Drugs Could Change Everything
Nvidia’s Rough Week… And Why Users Start & Stop GLP-1 Drugs 1/31/25
Novo Nordisk, Eli Lilly and the GLP-1 economy
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.